Abstract
Metabolic syndrome (MetS) is closely linked to cancer development, with emerging evidence suggesting its association with pulmonary carcinoma. However, causal relationships remain unclear due to observational study limitations. Employing Mendelian randomization, we investigated the causal link between MetS and lung cancer (LC) susceptibility. The data utilized in this study were obtained from the publicly available genetic variation summary database. The causal relationship was assessed using the inverse variance weighting method (IVW), weighted median method, and MR-Egger regression. A sensitivity analysis was carried out to confirm the robustness of the findings. Furthermore, risk factor analyses were conducted to explore potential mediators. Utilizing various analyses, MetS demonstrated a significant positive association with LC (OR, 1.22; 95% CI, 1.09-1.37, p = 7.57 × 10⁻⁴), lung squamous cell carcinoma (LUSC) (OR, 1.47; 95%, 1.23-1.75, p = 2.22 × 10⁻⁵), and small cell lung cancer (SCLC) (OR, 1.76; 95% CI, 1.37-2.26, p = 8.20 × 10⁻⁶) but not lung adenocarcinoma (LUAD) (OR, 1.08; 95% CI, 0.94-1.24, p = 0.28). Risk factor analyses indicated that smoking, alcohol, body mass index, education, and type 2 diabetes might mediate the association. This study genetically validates and reinforces the evidence of MetS increasing the incidence of LC, including both LUSC and SCLC, especially among individuals with abdominal obesity. It provides valuable insights for the development of lung cancer prevention strategies and directions for future research.
Introduction
Lung cancer (LC) is the leading cause of cancer-related mortality globally. While observational studies have suggested a link between metabolic syndrome (MetS)—a cluster of conditions including obesity, hypertension, and high blood glucose—and cancer, these findings are often confounded by shared lifestyle factors like smoking or reverse causality. This study addresses these uncertainties by using genetic proxies to untangle the causal relationship between MetS and its components with various lung cancer subtypes.
Methods
The researchers employed a Two-Sample Mendelian Randomization (MR) framework. MR utilizes single nucleotide polymorphisms (SNPs) as instrumental variables to represent exposure to MetS. Because these genetic variants are randomized at conception, they are generally unaffected by the confounding factors or reverse causality common in traditional observational research.
Datasets and Analysis
The study relied on large-scale Genome-Wide Association Study (GWAS) summary statistics from populations of European ancestry. Exposure data for MetS and its components (waist circumference, hypertension, fasting glucose, etc.) were sourced from the Complex Trait Genetics Lab and the UK Biobank. Outcome data for LC and its subtypes—Lung Adenocarcinoma (LUAD), Squamous Cell Lung Carcinoma (LUSC), and Small Cell Lung Carcinoma (SCLC)—were obtained from the GWAS Catalog. The primary analysis used the inverse variance weighting (IVW) method, supplemented by sensitivity analyses (MR-Egger and weighted median) to ensure robustness.
Results
Subtype Specificity and Causal Estimates
The MR analysis revealed that MetS does not affect all lung cancers equally. Significant positive associations were found for overall LC, LUSC, and SCLC, while no significant association was observed for LUAD. This suggests distinct biological pathways for different histological subtypes.
Key findings include:
- Overall Lung Cancer: OR 1.22 (95% CI, 1.09–1.37).
- LUSC: OR 1.47 (95% CI, 1.23–1.75).
- SCLC: OR 1.76 (95% CI, 1.37–2.26).
The Role of Abdominal Obesity and Mediation
Among MetS components, waist circumference (WC) emerged as the most potent predictor, nearly doubling the risk for SCLC (OR 2.02). Mediation analysis further suggested that MetS is genetically associated with an increased proclivity for high-risk behaviors, such as smoking (OR 9.52) and alcohol consumption, which may drive oncogenesis.
Discussion and Conclusion
This study provides strong genetic evidence that metabolic syndrome is a causal risk factor for lung cancer, particularly the squamous and small cell subtypes. The findings highlight the importance of managing abdominal obesity and metabolic health as part of lung cancer prevention strategies. While the study is limited by its focus on European ancestry and the need for further quantification of mediation effects, it offers a clear direction for future research into the molecular mechanisms—such as chronic inflammation and insulin resistance—linking metabolic dysfunction to lung malignancy.
Summary updated